Share
What makes a treatment targeted?
A targeted medicine acts on a particular protein or pathway involved in cancer growth or survival. Some are tablets; others are given through a drip into a vein (infusion). “Targeted” does not mean that healthy tissues cannot be affected or that treatment is free of side effects.
Different ways targeted medicines work
Some medicines block signals inside cancer cells; others attach to proteins on the cell surface or interfere with the blood-vessel supply supporting a tumour. Small-molecule medicines are often tablets or capsules, while many antibody medicines are given by infusion or injection. These categories overlap: an antibody-drug conjugate (ADC) is a targeted approach carrying a cell-killing medicine, and endocrine (hormone) therapy targets growth that depends on hormones.
The practical point is to know the exact medicine and why it fits your cancer. Treatments directed at different targets cannot be substituted simply because they are all called targeted therapy. A familiar brand name or a treatment used by another patient does not establish suitability.
Biomarkers and molecular testing
A biomarker is a measurable feature of the cancer, such as a protein or a genetic change. Not every targeted therapy requires a positive biomarker or molecular test. Some targeted medicines can be useful without identifying a specific mutation or protein marker. They are selected according to the cancer type, treatment setting and evidence for that medicine, rather than a matching molecular result.
Other targeted medicines require a particular biomarker result before they can be used for that cancer or treatment situation. Testing identifies whether the cancer meets the requirements for that specific treatment.
The exact biomarker, cancer type and treatment indication all matter. Finding a mutation does not automatically make a drug suitable, and a negative molecular test does not rule out every targeted treatment. Your oncologist will explain whether a test is needed and how its result affects your options.
Learn about molecular testingMaking sense of a test result
Testing may use an existing tumour sample, a new biopsy or, in selected circumstances, a blood sample. Protein staining and genetic sequencing answer different questions. The report should be interpreted with the pathology, treatment setting and quality of the sample. A finding may have an established treatment, support a clinical trial or have no proven treatment implication.
A negative result may mean the target was not found, but it can also reflect limitations of the sample or method. A tumour result is not automatically an inherited finding. If there are possible implications for relatives, a separate genetic assessment may be advised. Ask which part of the report changes your care, rather than assuming every listed variant needs treatment.
How treatment is selected
The doctor considers the exact result, diagnosis, stage, previous medicines, evidence and access. An alteration with the same name may have different implications in different cancers. A result can sometimes support a clinical trial rather than an established treatment.
Planning treatment and the first review
Before treatment starts, the team checks relevant blood tests and any medicine-specific requirements. Depending on the drug, these can include blood pressure, heart rhythm or pumping function, urine tests, infection screening or eye assessment. Existing symptoms help establish a baseline so that changes can be recognised.
Agree the schedule for early contact and follow-up. A medicine taken at home still needs regular review and a clear plan for side effects. Tell the team about planned surgery or dental procedures: some targeted medicines affect wound healing or bleeding, and their timing may need adjustment by the prescriber.
Planning your venous access
Some targeted therapies are tablets; others are given by infusion. For treatment into a vein (intravenous treatment), discuss a cannula (a small tube in a vein), a peripherally inserted central catheter (PICC, a longer line placed through an arm vein), or a port under the skin with your team. Oral medicines do not require a line to administer them.
Ports, PICCs, and venous accessTaking treatment safely
Ask about food instructions, missed doses and interactions. Prescription medicines, acid-reducing drugs, herbal remedies and supplements can change how some targeted drugs work. Do not adjust tablets or stop them without guidance.
Building a safe routine for tablets
Keep a written schedule with the medicine name, dose, treatment days and any rest days. Food rules are specific to the product. Some medicines interact with acid-reducing drugs, antibiotics, antifungals, supplements or particular foods; the oncology pharmacist can check your whole list.
Do not crush or open tablets and capsules unless the pharmacy confirms it is safe. If swallowing is difficult, ask about an appropriate alternative. Plan repeat prescriptions before the supply runs out. Missed-dose and vomiting instructions vary, so keep the advice for your medicine rather than relying on another patient’s routine.
Side effects and monitoring
Potential effects depend on the medicine and may involve the skin, bowel, blood pressure, liver, heart or lungs. Your team chooses the relevant monitoring. Report new symptoms early; a treatment break or adjustment may help manage toxicity.
Recognising symptoms and getting help
Report persistent diarrhoea, a troublesome rash, mouth sores, swelling, changes in vision or new numbness early. Skin changes are not always an allergy and may need specific treatment. Do not assume that a rash proves the medicine is working or stop important treatment without discussing it.
New breathlessness, chest pain, severe abdominal pain, significant bleeding, confusion or rapid deterioration needs urgent assessment. Fever or shaking chills also needs prompt contact, especially with a low blood count or combination treatment. Follow your regimen’s urgent-care instructions; different targeted medicines have different risks.
Resistance and repeat testing
A cancer can stop responding through several mechanisms. Repeat tissue or blood-based testing may sometimes identify a useful next step, but a negative result does not exclude all resistance changes. Discuss alternatives, clinical trials and the expected benefit of further treatment.
Frequently asked questions
Is targeted therapy the same as chemotherapy?
They work differently, although the categories can overlap. Conventional chemotherapy generally affects cell growth and division; targeted medicines act on selected biological processes. An ADC includes a cell-killing medicine linked to an antibody. Your medicine’s actual effects matter more than the label.
Does targeted mean there will be no side effects?
No. The target or affected pathway may also matter in healthy tissues. Side effects vary widely between medicines and can occasionally be serious. Ask for advice specific to your drug rather than assuming it will be easy to tolerate.
Does every patient need a large genetic panel?
No. Some targeted treatments do not require tumour genetic testing or a positive molecular result. They may be suitable based on the cancer type and treatment indication, even when molecular testing has not identified a matching target. Other medicines require a specific biomarker result, assessed with a protein test or a focused molecular test; broader sequencing can be useful in selected situations. Your oncologist will explain which tests are needed for the treatment being considered. More testing is not automatically more useful.
Does a mutation always mean there is a treatment?
No. Many findings do not have a proven treatment option. The exact alteration, cancer type and treatment setting all matter. A result may support research participation rather than a standard treatment.
Can the same mutation be treated the same way in different cancers?
Not necessarily. The surrounding biology can change how a medicine works. Some treatments have evidence across several tumour types, but others do not. The recommendation must match the evidence and the specific situation.
Can a blood test replace another biopsy?
Sometimes a liquid biopsy provides useful information, especially when tissue is difficult to obtain. It cannot answer every question, and a negative blood result may miss an alteration. Tissue testing or review may still be needed.
Will my relatives need testing because my tumour has a mutation?
Not automatically. Many tumour changes are acquired rather than inherited. Certain findings can prompt genetic counselling and a separate inherited-risk test. The team should explain which situation applies.
Are tablets weaker than an infusion?
No. How a medicine enters the body does not determine its strength or effectiveness. Oral targeted medicines can be potent and require careful dosing, interaction checks and monitoring.
What if I miss a dose or vomit after taking it?
Follow the instructions for that medicine or contact the oncology pharmacist. Do not automatically double, replace or repeat a dose. The correct approach depends on the drug and how much time has passed.
Can I take it with my usual medicines and supplements?
Only after an interaction check. Include medicines for acidity, infections, blood pressure and diabetes, plus herbal products. Do not stop essential medicines yourself; the prescribers can adjust the combination safely.
Do I have to avoid grapefruit or take tablets with food?
There is no single rule for all targeted treatments. Grapefruit interacts with some medicines, and food may increase or decrease absorption. Use the instructions for your exact product and ask if anything is unclear.
Why do I need blood tests if I feel well?
Some effects on the liver, blood counts or other organs may not cause early symptoms. Monitoring helps detect them and decide whether the dose remains appropriate. Feeling well does not replace the scheduled checks.
Does a rash mean treatment is working?
A rash is not a dependable way to judge your individual response. Report it so it can be assessed and treated. Benefit is judged using the cancer-specific assessment plan.
Can the dose be changed without losing all benefit?
A dose adjustment or supervised break may help manage side effects while allowing treatment to continue. The appropriate change is drug-specific. Do not make your own dose changes or assume a reduced dose has no value.
How long will I need treatment?
Some settings use a defined course, while others continue until progression or unacceptable side effects. Ask what the aim is, how benefit will be measured and what would trigger a change.
Why can a cancer become resistant?
Cancer cells can develop alternative growth pathways or other changes that reduce sensitivity. Repeat testing sometimes identifies a next option, but not always. A treatment change may involve another targeted drug, a different approach or a trial.
Can I travel, work or exercise?
Often, with planning around side effects and monitoring. Carry your medicine list and enough prescribed supply, and discuss storage, time-zone changes and access to care. New symptoms during travel should still be reported promptly.
What should I ask before agreeing to treatment?
Ask which target is being treated, what evidence supports this choice, what benefit is expected, what alternatives exist and which side effects need urgent attention. Confirm the tablet or infusion schedule and the review plan.
